Cianergoline

Cianergoline
Clinical data
Other names355/1057; 6-Methyl-8β-(2-cyano)propionamidoergoline; 2-Cyano-3-(6-methylergolin-8β-yl)propionamide; 2-CMEBP
Drug classDopamine receptor agonist; Antihypertensive agent
ATC code
  • None
Identifiers
  • 3-[(6aR,9S,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]-2-cyanopropanamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H22N4O
Molar mass322.412 g·mol−1
3D model (JSmol)
  • CN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CC(C#N)C(=O)N
  • InChI=1S/C19H22N4O/c1-23-10-11(5-12(8-20)19(21)24)6-15-14-3-2-4-16-18(14)13(9-22-16)7-17(15)23/h2-4,9,11-12,15,17,22H,5-7,10H2,1H3,(H2,21,24)/t11-,12?,15-,17-/m1/s1
  • Key:LVMVXZOPCAMYHC-QOAXCGLXSA-N

Cianergoline (INNTooltip International Nonproprietary Name), also known as 355/1057 or as 2-cyano-3-(6-methylergolin-8β-yl)propionamide (2-CMEBP), is a dopamine receptor agonist described as an antihypertensive agent of the ergoline family which was never marketed. It has atypical properties as a dopamine receptor agonist compared to other ergolines, for instance having less central activity and showing predominant cardiovascular effects. In addition to its dopamine receptor agonism, cianergoline may interact with α-adrenergic receptors, which may or may not also be involved in its antihypertensive effects. The drug was first described in the scientific literature by 1983. It was studied for treatment of essential hypertension.

See also